DOCS stock sentiment todayDoximity, Inc.
Sentiment verdict
Gossip first, financials second — HOT at 85% confidence.
Last updated · cached analysis, refreshes periodically
DOCS
Doximity, Inc.A high-margin monopoly on physician networking that is successfully pivoting from simple advertising to sophisticated AI-driven clinical workflow tools.
Pick a name and you can add your own 1-, 3- and 6-month price calls — no account needed. The needle above shows where the crowd sits. Calls lock 48 hours after you make them, so every scorecard stays honest.
You'll show up on boards and The Floor under this name. Add an email later to keep your history.
No account needed. You can add an email later to keep your calls.
Already have an account? Sign in
See exactly how analyst targets, gossip sentiment and momentum are weighted into this 6-month forecast.
Sign in to go Pro →Full model breakdown (analyst / gossip / momentum weights) is a Pro feature. Modelled for DOCS. Not financial advice.
Price · last 12 months
Gossip
Market sentiment has shifted significantly positive following a massive Q2 earnings beat and raised guidance. The narrative has moved from 'slowing ad spend' to 'AI-enabled clinical efficiency,' with investors cheering the rapid adoption of their Portal and AI tools.
- ·Client adoption of 'Programmatic' buying
- ·Hiring of new CFO (Tiffany Mapel)
- ·High short interest covering after recent earnings surge
- ·Expansion into clinical workflow and scheduling
Financial
Exceptional fundamental profile characterized by software-like margins (40%+ EBITDA margins) and a fortress balance sheet with zero debt. Revenue growth has re-accelerated into the high teens.
- ·Gross Margins exceeding 85%
- ·Rule of 40 score consistently above 50
- ·Free Cash Flow yield is robust compared to SaaS peers
- ·Repurchased $100M+ in stock recently
Conviction
Whose money is actually in the stock — insider open-market trades and the patience of the institutional holder base.
Mixed conviction — no decisive signal from insiders or the holder base.
- ·No open-market insider trades in the last 120 days.
Pro shows every named insider trade in the window (buyer, title, size, price, and whether it was a pre-scheduled 10b5-1 sale) plus the full holder register split into patient capital and fast money.
Unlock with Pro →Source: SEC EDGAR Form 4 + 13F holder register. Option exercises, grants, gifts and tax withholding are excluded — only open-market purchases and sales count. Not financial advice.
Risks
- ·Concentration of revenue within the top 20 pharmaceutical companies
- ·Potential saturation of the US physician market (80% already on platform)
- ·Strict regulatory environment regarding medical data and AI
Peer temperature
How direct competitors stack up against DOCS right now.
- NEUTRALVEEVVeeva Systems
COLDER — slower growth profile and trading at a higher price-to-sales multiple compared to DOCS' current re-acceleration.
See full analysis → - COLDTDOCTeladoc Health
COLDER — struggling with massive net losses and a lack of clear moat in a commoditized telehealth market.
See full analysis → - NEUTRALHQYHealthEquity
NEUTRAL — stable growth in health savings but lacks the high-margin digital advertising and AI-upside of the Doximity platform.
See full analysis →
- DOCS+15.6%
- VEEV+9.6%
- TDOC+46.7%
- HQY+15.8%
Analyst price target
Consensus average of 19 analysts · median 28.00
Source: StockAnalysis.com · updated 2026-10-21
AI-generated analysis for informational purposes only. Not financial advice.